Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Nixle, a secure community information tool, which has been rapidly adopted by over 1,800 law enforcement agencies across the country, is now offering its free technology to hospitals and schools to provide critical real-time alerts on the H1N1 Flu.
Optimal control of the spread of the seasonal flu and H1N1 is achieved by prioritizing vaccinations for schoolchildren and for adults aged 30 to 39 in the United States. Those are the findings of a new study by Clemson University mathematician Jan Medlock and colleague Alison Galvani of the Yale University School of Medicine.
Focus Diagnostics, the infectious disease diagnostics business of Quest Diagnostics Incorporated, today announced that its Influenza A H1N1 (2009) Real Time RT-PCR test is now available as a test kit for use by "high complexity" clinical laboratories in the U.S.
With the seasonal flu season approaching and uncertainty over whether swine flu will become more severe, new research published by Yale School of Public Health has found that more people are likely to avoid illness if vaccines are given out first to those most likely to transmit viruses, rather than to those at highest risk for complications.
According to the latest WHO report out Wednesday, the number of confirmed H1N1 (swine) flu deaths since its emergence in April has reached 1,799 - a jump from 1,462 deaths since the agency's last update, Agence France-Presse/the Australian reports.
The development of new antiviral drugs has had a tremendous impact on the quality of life and life expectancy of HIV-positive and AIDS patients, as the drugs effectively disrupt the replication cycle of the HIV virus. Yet the regular use of those drugs - such as zidovudine (also known as azidothymidine or AZT), protease inhibitors, and highly active antiretroviral therapy (HAART) involving multidrug therapies - has led to resistant HIV strains.
Safeway Inc. (NYSE:SWY) added to its leadership reputation in health care reform and cost control by offering seasonal flu vaccines in its U.S. stores at a substantial savings compared with the cost of doctor-administered vaccines. The lower cost will help consumers and businesses control health care spending in a challenging economy.
Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.
The COSHAR Foundation has enhanced its national immunization awareness campaign, Protecting our Future: The COSHAR Foundation Immunization Project, by updating its free immunization toolkits with new materials, including updated information about autism and vaccines and information on H1N1 flu. The new toolkits are available now.
The City of New Orleans Department of Homeland Security and the City of New Orleans Fire Department have selected Upp Technology, Inc. to help improve the efficiency of their day-to-day operations. New Orleans chose Upp’s irms|EM (Emergency Management) solution, deployed on the irms|Go-Kit for a mobile inventory management system allowing the city to track inventory through the use of bar-coding at their warehouses and storerooms. Furthermore, the same Go-Kits can then be redeployed to the field in times of emergency to receive and distribute cots, water, food, and other critical supplies needed in Emergency Response.
Anthem Blue Cross and Blue Shield in Maine has announced that it will offer coverage for the administration of the H1N1 (swine flu) vaccine when it becomes commercially available to the general public. The vaccine administration will be covered for members whose benefit plans provide coverage for vaccines.
Department of Commerce (DOC) Secretary Gary Locke, Department of Health and Human Services (HHS) Secretary Kathleen Sebelius, and Homeland Security (DHS) Secretary Janet Napolitano today announced new guidance for businesses to plan for and respond to the upcoming flu season.
"Northern hemisphere countries have so far ordered more than one billion doses of swine flu vaccine, the World Health Organisation said Tuesday, sparking warnings over shortages," Agence France-Presse reports. While some countries, including Greece, The Netherlands, Canada and Israel, have ordered enough vaccine to inoculate their citizens, "[o]thers, such as Germany, the United States, Britain and France, have put in orders that would cover between 30 and 78 percent of people," the news service writes.
The cruise ship Marco Polo, whose round-Britain cruise had to be cancelled because hundreds of passengers became ill with the vomiting bug Norovirus, has been totally disinfected by SitexOrbis' revolutionary infection control fogging service in just 5 hours at the Tilbury docks.
Doctors and hospitals nationwide expect a surge in H1N1 influenza cases during the upcoming flu season. In a new video and the tips below, Yvonne Maldonado, MD, chief of infectious disease at Lucile Packard Children’s Hospital at Stanford, explains what every parent should know about H1N1 flu as children head back to school.
CEL-SCI Corporation has announced that it is expanding the scope of its work towards creating a novel treatment and vaccination against the current H1N1 virus, as well as a future mutated form in which the virus has acquired greater morbidity and mortality.
Sinovac Biotech Ltd. announced today positive top-line results from the completed clinical trial for its internally-developed H1N1 vaccine. The clinical data unblinding conference was held in Beijing on the afternoon of August 17, 2009. Notably, Sinovac is the first company worldwide to complete clinical trials for the H1N1 vaccine.
Novavax, Inc. (Nasdaq: NVAX) announced positive preclinical results with Novavax's 2009 novel H1N1 influenza virus-like particle (VLP) vaccine. The study, conducted by scientists from Novavax and the Centers for Disease Control and Prevention (CDC) based in Atlanta, GA, under a collaborative agreement, represents the first efficacy report of a 2009 novel H1N1 vaccine in ferrets. The ferret model is widely accepted to be the most appropriate animal model for evaluating influenza disease and vaccines. Novavax scientists designed the vaccine using recombinant virus like particles (VLP) technology against an H1N1 virus strain (A/California/04/2009) isolated in the beginning of the 2009 H1N1 outbreak.
Hard to Treat Diseases (HTDS.PK) Mellow Hope, an operating subsidiary of HTDS, is pleased to report that its clinical trial is currently being processed.
CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced today that the U.S. Food and Drug Administration (FDA) has licensed the company’s newest vaccine filling and packaging facility, located in Kankakee, Ill. The facility, part of an investment to expand CSL’s U.S. influenza vaccine production capabilities, includes a high-speed, single-dose vaccine syringe filling line.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.